Journal of Medicinal Chemistry · 2013 · 38 citations · 28 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyCardiac Ion ChannelsChannel StructureIon Channel PharmacologyIon Channel PhysiologyIon ChannelsLigand BindingAromatic HeterocyclesDofetilide TherapyDrug Binding To Ion ChannelsHeteroaromatic CompoundsHuman Ether-a-go-go-related Gene (Herg) Channel InhibitionIon Channel Drug BindingPyridine ChemistryRadioligand Binding Assays
Drug-induced blockade of the human ether-a-go-go-related gene K(+) channel (hERG) represents one of the major antitarget concerns in pharmaceutical industry. SAR studies of this ion channel have shed light on the structural requirements for hERG interaction but most importantly may reveal drug design principles to reduce hERG affinity. In the present study, a novel library of neutral and positively charged heteroaromatic derivatives of the class III antiarrhythmic agent dofetilide was synthesized and assessed for hERG affinity in radioligand binding and manual patch clamp assays. Structural modifications of the pyridine moiety, side chain, and peripheral aromatic moieties were evaluated, thereby revealing approaches for reducing hERG binding affinity. In particular, we found that the extra rigidity imposed close to the positively charged pyridine moiety can be very efficient in decreasing hERG affinity.
28
Andrea Cavalli, Elisabetta Poluzzi, Fabrizio De Ponti et al. · Journal of Medicinal Chemistry · 2002 · 385 citations · Full text
Physicochemical Features of the hERG Channel Drug Binding Site
David Fernández, Azad Ghanta, Gregory W. Kauffman et al. · Journal of Biological Chemistry · 2004 · 265 citations · Full text
Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death
Marie L. De Bruin, Monica Pettersson, R.H.B. Meyboom et al. · European Heart Journal · 2005 · 245 citations · Full text
Pharmacy, Cardiology, Pharmacology +17